When to Repeat A1C if 5.8%
An A1C of 5.8% places the patient in the prediabetes range (5.7–6.4%) and should be repeated annually, with consideration for more frequent testing if additional risk factors are present. 1, 2
Understanding the Result
An A1C of 5.8% falls within the prediabetes (increased risk for diabetes) range of 5.7–6.4%, which identifies individuals at elevated risk for progression to diabetes but who do not yet meet diagnostic criteria. 1, 3, 2
This value does not meet the diabetes diagnostic threshold of ≥6.5%, so no confirmatory testing for diabetes is needed at this time. 1, 3, 2
The risk of developing diabetes follows A1C levels as a continuum—higher values within the prediabetes range confer progressively greater risk for future diabetes. 3
Recommended Repeat Testing Interval
People with prediabetes (A1C 5.7–6.4%) should be tested yearly. 2
The 2023 American Diabetes Association Standards of Care explicitly recommend annual testing for individuals with prediabetes. 2
This yearly interval allows timely detection of progression to diabetes while avoiding unnecessary overuse of testing. 2
When to Consider More Frequent Testing
More frequent testing (shorter than 12-month intervals) should be considered based on:
Initial A1C result within the prediabetes range: An A1C of 5.8% is at the lower end of prediabetes; patients with values closer to 6.4% may warrant testing every 6 months. 1
Presence of multiple diabetes risk factors, including: 1, 2
- Overweight or obesity (BMI ≥25 kg/m² or ≥23 kg/m² in Asian Americans)
- First-degree relative with diabetes
- High-risk ethnicity (African American, Latino, Native American, Asian American, Pacific Islander)
- History of cardiovascular disease
- Hypertension (≥130/80 mmHg or on therapy)
- HDL cholesterol <35 mg/dL or triglycerides >250 mg/dL
- Polycystic ovary syndrome
- Physical inactivity
- Conditions associated with insulin resistance (severe obesity, acanthosis nigricans)
Worsening BMI or deteriorating risk factor profile during follow-up warrants more frequent monitoring. 2
History of gestational diabetes: These patients should have lifelong testing at least every 3 years, but annual testing is appropriate given the elevated baseline risk. 2
Clinical Management at A1C 5.8%
Intensive lifestyle intervention is the primary strategy, focusing on structured diet modification and regular physical activity with multiple follow-up contacts to reinforce behavior change. 1, 2
Metformin is not first-line therapy for prediabetes; lifestyle modification takes precedence. 4, 5
Screen and address cardiovascular risk factors including lipids, blood pressure, and smoking status. 4
Patient education about diabetes symptoms, the importance of lifestyle changes, and the rationale for annual monitoring. 2
Common Pitfalls to Avoid
Do not wait 3 years to retest as recommended for individuals with normal glucose metabolism; prediabetes requires annual monitoring. 1, 2
Do not initiate diabetes medications such as metformin without confirmed diabetes diagnosis (A1C ≥6.5% on two occasions or other diagnostic criteria). 4, 5
Do not assume the patient will progress to diabetes; intensive lifestyle intervention can prevent or delay progression in many cases. 2
Do not overlook conditions that may affect A1C reliability (hemoglobinopathies, anemia, recent blood loss), though these are less relevant for monitoring than for diagnosis. 3, 6
Evidence for Annual Testing in Prediabetes
Research demonstrates that patients with A1C 5.6–6.0% have an annual diabetes incidence of 2.5%, and those with A1C 6.1–6.9% have an incidence of 7.8% per year. 7
An A1C of 5.8% predicts moderate risk for progression, justifying annual surveillance to detect conversion to diabetes when intervention strategies can be optimized. 7
The 2023 ADA guidelines represent high-quality expert consensus based on longitudinal data linking prediabetes A1C values to future diabetes risk. 3, 2